Gilead Sciences Inc. (NASDAQ:BROWN) is one of Goldman Sachs’ top healthcare stocks. On March 10, Jefferies initiated coverage of Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target. The research firm has touted the company’s earnings per share growth and margin expansion prospects as part of its bullish thesis.
Kurhan / Shutterstock.com
According to the research firm, the company is not facing any near-term intellectual property gap or significant operating leverage. Instead, it is well positioned with its HIV franchise and subsequent product prospects. The research firm is also optimistic about the company’s prospects with the launch of Yetzugo in pre-exposure prophylaxis.
Additionally, Gilead Sciences is making significant progress in developing its pipeline. A Phase 3 RAINIER trial for the drug povetacicept has already met primary and secondary endpoints in the treatment of immunoglobulin A nephropathy (IgAN).
Amid the project’s development, Gilead also signed a $7.8 billion deal to acquire blood cancer drug developer Arcellx. The agreement follows a long partnership, signed in 2022, for the commercialization of drugs to combat multiple myeloma.
Gilead Sciences, Inc. (NASDAQ:GILD) is a US-based biopharmaceutical company that discovers, develops and commercializes innovative medicines for life-threatening diseases, particularly in virology, oncology and inflammation. It is known for its leadership in antiviral therapies for HIV, hepatitis B and C, and COVID-19, with a strong focus on expanding its impact globally, including in Asia.
While we recognize GILD’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: The 40 most popular stocks among hedge funds by 2026 and the 11 best affordable growth stocks to buy now.
Disclosure: None. Follow Insider Monkey on Google News.